TKI258

DRUG16 trials

Sponsors

Novartis, Novartis Pharmaceuticals, Korean Cancer Study Group, National Cancer Centre, Singapore

Conditions

Acute Myeloid LeukemiaAdenocarcinoma, ScirrhousAdvanced Solid MalignanciesAdvanced Solid TumorsAdvanced Solid Tumors, Excluding Breast CancerAdvanced/ Metastatic Renal Cell CancerCancerColorectal Cancer

Phase 1

TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma

TerminatedNCT00243763

NovartisMultiple Myeloma

Target: 64Updated: 2009-11-23

Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia

TerminatedNCT00279773

Novartis PharmaceuticalsAcute Myeloid Leukemia

Start: 2004-09-30Updated: 2010-06-30

Safety of TKI258 in Advanced/Metastatic Melanoma Subjects

CompletedNCT00303251

Novartis PharmaceuticalsMelanoma

Start: 2006-04-30Updated: 2021-03-11

Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid Malignancies

CompletedNCT00669097

Novartis PharmaceuticalsAdvanced Solid Malignancies

Start: 2008-04-30Updated: 2020-12-21

A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer

CompletedNCT00715182

Novartis PharmaceuticalsAdvanced/ Metastatic Renal Cell Cancer

Start: 2008-07-31End: 2012-07-31Updated: 2020-12-21

Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors

CompletedNCT01155713

Novartis PharmaceuticalsCancer, Neoplasm, Tumors

Start: 2010-07-31End: 2013-11-30Updated: 2020-12-21

Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors

CompletedNCT01421004

Novartis PharmaceuticalsAdvanced Solid Tumors, Excluding Breast Cancer

Start: 2011-12-31End: 2014-07-31Updated: 2020-12-21

Phase I Dose Escalating Study of TKI258

CompletedNCT01471548

Novartis PharmaceuticalsAdvanced Solid Tumors

Start: 2008-09-30End: 2012-05-31Updated: 2020-12-21

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors

CompletedNCT01596647

Novartis PharmaceuticalsAdvanced Solid Tumors, Excluding Breast Cancer

Start: 2012-05-31End: 2014-07-31Updated: 2020-12-21

Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer

TerminatedNCT02720926

National Cancer Centre, SingaporeColorectal Cancer, Gastric Cancer

Start: 2011-09-30End: 2012-01-31Updated: 2016-03-28

Phase 2

Phase II Study of TKI258 in Advanced Urothelial Carcinoma

CompletedNCT00790426

Novartis PharmaceuticalsUrothelial Cancer

Start: 2010-03-31End: 2012-04-30Updated: 2020-12-19

Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer

CompletedNCT00958971

Novartis PharmaceuticalsMetastatic Breast Cancer

Start: 2009-07-31End: 2011-03-31Updated: 2020-12-19

Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation

CompletedNCT01058434

Novartis PharmaceuticalsRelapsed or Refractory Multiple Myeloma

Start: 2010-05-31End: 2013-02-28Updated: 2020-12-19

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

CompletedNCT01379534

Novartis PharmaceuticalsEndometrial Cancer, Second-line Treatment, Solid Tumors and Advanced Endometrial Cancer +1

Start: 2011-11-30End: 2014-03-31Updated: 2015-05-20

A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients

CompletedNCT01576380

Novartis PharmaceuticalsAdenocarcinoma, Scirrhous, Linitis Plastica, Neoplasms +3

Start: 2012-06-30End: 2013-09-30Updated: 2017-02-27

Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer

CompletedNCT01741116

Korean Cancer Study GroupHormone Refractory Prostate Cancer

Start: 2012-11-30End: 2016-10-31Updated: 2021-02-18

Related Papers

Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.

2015-05-1366 citations

Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.

2014-10-3081 citations

Phase 1 study assessing dovitinib (TKI258) on the pharmacokinetics of caffeine, diclofenac, omeprazole, and midazolam in patients with advanced solid tumors.

Journal of Clinical Oncology2014-05-201 citations